Ember Therapeutics, Inc.

Equities

EMBT

US29082W1099

Market Closed - OTC Markets Other stock markets 07:32:31 20/09/2023 pm IST			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2019	Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI
2018	Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI

Knight Therapeutics Inc. and Ember Therapeutics, Inc. Expand Distribution Partnership

July 06, 2016 at 05:30 pm IST

Knight Therapeutics Inc. and Ember Therapeutics, Inc. announced an expansion of their exclusive distribution agreement signed in August 2015. Pursuant to the amendment, Knight's territorial rights to Ember's Bone Morphogenetic Protein-7 (BMP-7) pipeline, which originally included Canada, Israel, Russia and sub-Saharan Africa, have been expanded to include Romania and the Caribbean. Additionally, Knight has acquired the exclusive distribution rights for two diversified products recently acquired by Ember: Migralex, a commercially-available over-the-counter medication for treating pain, and ICX-RHY/Vavelta, a development stage regenerative medicine asset, in all of the above-mentioned territories.

Latest news about Ember Therapeutics, Inc.

Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..	16/19/16	CI
Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..	16/18/16	CI
Ember Therapeutics, Inc. acquired the assets of of Dermasilk Brands, Inc. from Midwood Distributors, Inc. for $1.3 million.	08/16/08	CI
Knight Therapeutics Inc. and Ember Therapeutics, Inc. Expand Distribution Partnership	06/16/06	CI
Ember Therapeutics, Inc. entered into a definitive agreement to acquire the assets of Migralex, Inc. for $0.87 million.	21/16/21	CI
Ember Therapeutics, Inc. acquired ICX-RHY/Vavelta from Intercytex Limited for $1.1 million.	16/16/16	CI
American Home Alliance Corp will Change its Ticker to EMBT from AHLL	24/16/24	CI
AMERICAN HOME ALLIANCE CORP will Change its Name to Ember Therapeutics, Inc	24/16/24	CI
Ember Therapeutics, Inc. acquired American Home Alliance Corp. in a reverse merger transaction.	03/16/03	CI
Ember Therapeutics, Inc. Announces Initial Positive Results from a Phase 2 Trial of BMP-7	20/15/20	CI
Mariel Therapeutics, Inc. acquired Ember Therapeutics, Inc. from Third Rock Ventures II, L.P. of Third Rock Ventures II, L.P. and others for $6 million.	12/15/12	CI
Ember Therapeutics, Inc. acquired Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation.	31/14/31	CI
Ember Therapeutics, Inc. Announces Publication of Key Preclinical Data Demonstrating Inhibition of Transient Receptor Potential Vanilloid	27/12/27	CI
Ember Therapeutics, Inc. Announces Management Appointments	30/12/30	CI
Ember Therapeutics, Inc. Closes License Deal with Joslin Diabetes Center	31/12/31	CI

Chart Ember Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company